Published on in Vol 10, No 10 (2021): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/24969, first published .
Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Journals

  1. Seiberl M, Feige J, Hilpold P, Hitzl W, Machegger L, Buchmann A, Khalil M, Trinka E, Harrer A, Wipfler P, Moser T. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. International Journal of Molecular Sciences 2023;24(4):4067 View
  2. Giovannoni G, Mathews J. Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review. Neurology and Therapy 2022;11(2):571 View
  3. Centonze D, Amato M, Brescia Morra V, Cocco E, De Stefano N, Gasperini C, Gallo P, Pozzilli C, Trojano M, Filippi M. Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Therapeutic Advances in Neurological Disorders 2023;16 View
  4. Aran K, Gupta G, Singh S. Cryptotanshinone ameliorates cladribine-induced cognitive impairment in rats. Asian Pacific Journal of Tropical Biomedicine 2023;13(7):296 View